Indiana University Center for Pediatric Pharmacology and Precision Medicine (ICPPPM)
Programmatic Goal/Theme: Biomarkers that predict the efficacy and toxicity of chemotherapies for children with cancer to optimize treatment of individual pediatric patients.
Goals Project 1: Using a precision medicine approach (incorporating focused NGS based tumor therapeutic strategies to relapsed and refractory pediatric sarcomas
The Development of Thermally-activated Metalloenediynes for Cancer Therapy
Goals: The major goals of this project is to select and characterize Metalloenediyne derivatives using PK/PD and efficacy studies in tumor xenografts.
Development of SHP2 inhibitors for targeted anti-cancer therapy
Goal: screen prioritized SHP2 inhibitors using in vitro and in vivo models of lung and brain cancer.
Preclinical Assessment of Therapeutic Response-Related Molecular Biomarkers in Pediatric Osteosarcomas
Goal: Evaluate novel multi-targeted therapy based on precision genomics data mining of CNVs in osteosarcoma.
Development of a Novel Oncolytic Therapeutic to Treat Glioblastoma
Goal: test novel mammalian reoviruses with increased capacity to induce cell death in models of GBM
J. Carter, L. Cheng, J. Zucker, M. Marshall, K.E. Pollok, M. Murray, L. Li, and J. Renbarger. (2017) Use of Precision Medicine Molecular Profiling of Baseline Tumor Specimen May Not Benefit Outcomes in Children with Relapsed, Refractory, or Rare Pediatric Sarcomas. Clin Pharmacol Ther. Mar;101(3):328-330. PMCID: PMC5511378.
H. Wang, S. Cai, B.J. Bailey, M.R. Saadatzadeh, E. Tonsing-Carter, J. Ding, T.M. Georgiadis, T.Z. Gunter, E.C. Long, R.E. Minto, K.R. Gordon, S.E. Sen, W. Cai, J.A. Eitel, D.L. Waning, L.R. Bringman, C.D. Wells, M.E. Murray, J. Sarkaria, L.M. Gelbert, D.R. Jones, A. Cohen-Gadol, L.D. Mayo, H.E. Shannon, and K.E. Pollok. 2017. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an Mdm2 Antagonist. J Neurosurgery. 126(2):446-459. doi: 10.3171/2016.1.JNS152513. Epub 2016 May 13; PMID: 27177180.
K. Bijangi-Vishehsaraei, M. Reza Saadatzadeh, H. Wang, A. Nguyen, M. M. Kamocka, W. Cai, A.A. Cohen-Gadol, S. L. Halum, J. N. Sarkaria, K. E. Pollok*, and A. R. Safa. (*co-corresponding authors). 2016. Sulforaphane suppresses growth of glioblastoma (GBM) cells, GBM stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. 2017. Journal of Neurosurgery, Epub 2017 Jan 6.
E. Tonsing-Carter, A.L. Sinn, J. Silver, K.M. Peterson, B.J. Bailey, C.M. Eischen, H. Wang, H.S. Shannon, J. Ding, S. Cai, P.R. Territo, G.E. Sandusky, L.D. Mayo, J. Li, C.B. Marchal, H. Hanenberg, and K.E. Pollok. 2015. Potentiation of carboplatin-mediated DNA damage by the MDM2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model. Mol Cancer Ther, 14(12):2850-63. PMCID: PMC4674357 Featured Highlight Article.
S. Cai, H. Wang, A.R. Baluyut, A. Ernstberger, B. Juliar, A.L. Sinn, L.D. Mayo, W. S. Goebel, and K.E. Pollok. Humanized bone-marrow xenograft model as a pre-clinical tool to assess therapy-mediated hematotoxicity. 2011. Clinical Cancer Research. 8:2195-2206. PMCID: PMC3078977.
Faculty Research Team
Additional Research Team Members:
The research team also includes Adily Elmi, MS (Research Associate), Barbara Bailey (Senior Research Technician, Lab Manager), and Courtney Hemenway (Research Technician). Research staff within the In Vivo Therapeutics Core include Dawn Bullock (Research Technician), Melissa Trowbridge (Research Technician), and Tony Sinn (Core Manager). Within the Angio BioCore, research staff includes Matt Repass (Research Technician) and Emily Sims (Core Manager).